Pharmsintez's loss under RAS for 3 months of 2025 amounted to 74.4 million rubles, an increase of 4.6% compared to 71.1 million rubles in the previous year. Revenue decreased by 38.5% to ₽25.6 million from ₽41.6 million a year earlier.